Nikoletta L. Kallinteris

Results from a Phase I Clinical Study of the Novel Ii-Key/HER-2/<i>neu</i>(776–790) Hybrid Peptide Vaccine in Patients with Prostate Cancer

Sonia A. Perez, Nikoletta L. Kallinteris, Stratos Bisias et al. · Clinical Cancer Research · 2010 · 65 citations

Ii-Key/HER-2/neu(776-90) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors

Nectaria N. Sotiriadou, Nikoletta L. Kallinteris, Angelos D. Gritzapis et al. · Cancer Immunology Immunotherapy · 2006 · 52 citations · Full text

Tumor Immunology, Her-2/neu+ Tumors, Cancer Immunosurveillance +11

Induction of potent CD4⁺ T cell‐mediated antitumor responses by a helper HER‐2/<i>neu</i> peptide linked to the Ii‐Key moiety of the invariant chain

Ioannis F. Voutsas, Angelos D. Gritzapis, Louisa G. Mahaira et al. · International Journal of Cancer · 2007 · 47 citations

Ii-Key/HER-2/ neu MHC class-II antigenic epitope vaccine peptide for breast cancer

Michael E. Gillogly, Nikoletta L. Kallinteris, Minzhen Xu et al. · Cancer Immunology Immunotherapy · 2004 · 46 citations · Full text

Vaccination, Vaccine Target, Immunology +10

Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer

David E. Gerber, Leora Horn, Michael Boyer et al. · Annals of Oncology · 2018 · 40 citations · Full text